-
Day of reckoning arrives for social media after US court loss
-
World Cup concerns are exaggerated, says FIFA vice-president
-
NBA team owners approve exploring expansion to Seattle and Las Vegas
-
UK teenagers to trial social media bans, digital curfews
-
World champions England still 'unfinished' ahead of Six Nations, says Mitchell
-
Rybakina outlasts Pegula to reach Miami Open semis
-
Barca build huge lead on Real Madrid in Women's Champions League quarters
-
Alleged Rihanna mansion shooter pleads not guilty
-
US says Iran talks continue, will 'unleash hell' if no deal
-
UN designates African slave trade as 'gravest crime against humanity'
-
Trump's Beijing trip rescheduled for May, after Iran delay
-
No more excuses: World Cup pressure is on for host USA
-
US EPA issues waiver for E15 fuel to address oil supply issues
-
Grieving families hail court victory against Instagram, YouTube
-
Internet providers not liable for music piracy by users: top US court
-
Gaza civil defence says Israeli strike kills one, tents on fire
-
UK govt denies cover-up after PM ex-aide's phone stolen
-
California jury finds Meta, YouTube liable in social media addiction trial
-
Oil prices slip, stocks rally on Mideast peace hopes
-
South Africa police clash with anti-immigrant protesters
-
Gattuso says Italy's World Cup play-off 'biggest match' of career
-
Sakamoto leads skating swansong with 'Time to Say Goodbye' at worlds
-
Spanish PM says Middle East war 'far worse' than Iraq in 2003
-
First Robot: Melania Trump brings droid to White House event
-
Oldest dog DNA suggests 16,000 years of human companionship
-
Iran media casts doubt on US peace plan
-
Rare mountain gorilla twins born in DR Congo: park authorities
-
Ex-midwife enthroned as first female Archbishop of Canterbury
-
AC Schnitzer: When Iconic Tuners Fall Silent
-
Senegal lodge appeal to Court of Arbitration for Sport over AFCON final decision
-
South Africa seal T20 series win in New Zealand
-
Study links major polluters to big climate damages bill
-
Ex-Google chief Matt Brittin made new BBC director-general
-
Iran likely behind attacks sowing fear among Europe's Jews: experts
-
'Relieved' McGrath claims career first crystal globe in slalom
-
US ski star Shiffrin wins overall World Cup title for sixth time
-
Trump names tech titans to science advisory council
-
Mideast war sparks long queues at Kinshasa petrol stations
-
US TV star details 'agony' over mother's disappearance
-
Tehran receives US plan to end Mideast war, as Iran fires at US carrier
-
Aviation, tourism, agriculture... the economic sectors hit by the war
-
Iran fires at US carrier as backchannel diplomacy aims to end war
-
Salah's long goodbye brings curtain down on golden era for Liverpool
-
Monaco: city of vice and a few virtues
-
AI making cyber attacks costlier and more effective: Munich Re
-
Defying Israeli bombs, Lebanese hold out in southern city of Tyre
-
War-linked power crunch pushes Sri Lanka to four-day week
-
Hungary says will phase out gas deliveries to Ukraine
-
Oil prices tumble, stocks rally on Mideast peace hopes
-
Maybach: Between Glory and a Turning Point
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
P.L.Madureira--PC